Abstract
Retinal dystrophies (RD) constitute a group of blinding diseases that are characterized by clinical variability and pronounced genetic heterogeneity. The different nonsyndromic and syndromic forms of RD can be attributed to mutations in more than 200 genes. Consequently, next generation sequencing (NGS) technologies are among the most promising approaches to identify mutations in RD. We screened a large cohort of patients comprising 89 independent cases and families with various subforms of RD applying different NGS platforms. While mutation screening in 50 cases was performed using a RD gene capture panel, 47 cases were analyzed using whole exome sequencing. One family was analyzed using whole genome sequencing. A detection rate of 61% was achieved including mutations in 34 known and two novel RD genes. A total of 69 distinct mutations were identified, including 39 novel mutations. Notably, genetic findings in several families were not consistent with the initial clinical diagnosis. Clinical reassessment resulted in refinement of the clinical diagnosis in some of these families and confirmed the broad clinical spectrum associated with mutations in RD genes.
Highlights
Retinal dystrophies (RD) are among the disorders with the highest level of heterogeneity
Causative mutations were detected in 25 of 50 cases which were analyzed with our custom RD panel
Of the 25 cases that remained unsolved using our RD panel, eight were selected for subsequent analysis applying whole exome sequencing (WES), in addition to a further 39 cases that were selected for direct WES analyses
Summary
Retinal dystrophies (RD) are among the disorders with the highest level of heterogeneity. Screening for deep intronic variants (denoted as V1–V7) in the ABCA4 gene [8] was performed in family CACD25 in which exome sequencing had revealed a single heterozygous missense mutation in ABCA4.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.